An observational study in Motility Disorder, Gastroparesis and Functional Dyspepsia, sponsored by University of Calgary. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by University of Calgary · Observational
This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and correlation of metrics with patient symptoms among healthy adults and patients diagnosed with upper abdominal motility disorders.
GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.
323 studies on the registry are indexed under Gastroparesis; 76 are open to participants now.
This study's planned enrollment of 400 is above the median of 100 across 80 observational studies indexed under Gastroparesis.
Browse Gastroparesis studies →University of Calgary is the lead sponsor of 703 studies on the registry; 196 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults living in the Calgary Alberta region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Population:
Patient Population:
Exclusion Criteria:
Healthy Population:
Patient Population:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with history of confirmed motility disorder.
Device: Gastric Alimetry System
Adults meeting all inclusion and exclusion criteria with no symptoms or history of motility disorder.
Device: Gastric Alimetry System
Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
Gastric electrical signal frequency
Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Pre-meal
Gastric electrical signal frequency
Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 1 hour
Gastric electrical signal frequency
Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 2 hours
Gastric electrical signal frequency
Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 3 hours
Gastric electrical signal frequency
Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 4 hours
Gastric electrical signal amplitude
Estimation of the power of the gastric electrical signal in the above frequency spectrum (μV) at a Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Pre-meal
Gastric electrical signal amplitude
Estimation of the power of the gastric electrical signal in the above frequency spectrum (μV) at a Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 1 hour
Gastric electrical signal amplitude
Estimation of the power of the gastric electrical signal in the above frequency spectrum (μV) at a Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 2 hours
Gastric electrical signal amplitude
Estimation of the power of the gastric electrical signal in the above frequency spectrum (μV) at a Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 3 hours
Gastric electrical signal amplitude
Estimation of the power of the gastric electrical signal in the above frequency spectrum (μV) at a Reliability of 90% and Confidence Interval (CI) of 95%
Time frame: Post meal at 4 hours
Safety - abdominal skin effects
Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal
Time frame: After removal of Gastric Alimetry array at approximately 4.2 hours post meal
Safety - abdominal skin effects
Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal
Time frame: 24 hours post study visit
Safety - abdominal skin effects
Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal
Time frame: 7 days post study visit
Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full
Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable
Time frame: Pre-meal
Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full
Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable
Time frame: Post meal at 1 hour
Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full
Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable
Time frame: Post meal at 2 hours
Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full
Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable
Time frame: Post meal at 3 hours
Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full
Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable
Time frame: Post meal at 4 hours
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.